SCHEMBL1819040

SCHEMBL1819040

Cc1ccccc1C(C)(Oc1ccccc1)C(N)=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.41
KMT2A Q03164 2/20 0.41
PPARA Q07869 5/20 0.35
PPARG P37231 4/20 0.35
PARP10 Q53GL7 1/20 0.35
KCNN4 O15554 2/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
ATM Q13315 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
PKM P14618 1/20 0.34
MYC P01106 1/20 0.33
HSD11B1 P28845 1/20 0.33
HSD11B2 P80365 1/20 0.33
MEN1 O00255 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C19 P33261 1/20 0.33
GABRA1 P14867 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1820578 0.89 KMT2A (0.38) MAPTKMT2APPARAPPARGPARP10
SCHEMBL1818643 0.84 ALDH1A1 (0.44) MAPTKMT2APPARAPPARGPARP10
SCHEMBL1819713 0.83 MAOB (0.42) MAPTKMT2AKCNN4MEN1
SCHEMBL1821869 0.83 KCNN4 (0.51) MAPTKMT2APPARAPPARGPARP10
SCHEMBL1823517 0.83 MAPT (0.40) MAPTKMT2APPARAPPARGPARP10
SCHEMBL1821619 0.81 CTNNB1 (0.49) MAPTKMT2APPARGPARP10ATM
SCHEMBL1818709 0.81 KMT2A (0.44) MAPTKMT2AL3MBTL1MEN1CTNNB1
SCHEMBL1819565 0.80 MAPT (0.38) MAPTKMT2APPARAPPARGPARP10
SCHEMBL1817766 0.80 CYP2C19 (0.38) MAPTKMT2APPARAPPARGKCNN4
SCHEMBL27757832 0.80 MAPT (0.55) MAPTKMT2APPARAPPARGPARP10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947712-B2 Antiarthritic agents; asthma; chronic obstructive pulminary diosrders; atherosclerosis; vision defects; hepatitis; central nervous system disorders; cardiovascular disorders; wound healing agents; restenosis; cirrhosis; multiple sclerosis; glomerulonephritis; graft versus host disease; antidiabetic agent WYETH LLC (US) 2011-05-24 US disclosed
US-20080269213-A1 8-Hydroxyquinoline compounds and methods thereof WYETH (US) 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269213-A1 8-Hydroxyquinoline compounds and methods thereof MMP8, MMP26, MMP9 MAPT 2414/4885KMT2A 4052/4885PPARA 2595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.